I would personally temper my expectations here a little on near term profitability.
Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.
EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.
If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.
The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.
- Forums
- ASX - By Stock
- EYE
- Nova Eye Medical (EYE) Discussion
Nova Eye Medical (EYE) Discussion, page-2480
-
- There are more pages in this discussion • 628 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
|
|||||
Last
21.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.19M |
Open | High | Low | Value | Volume |
22.3¢ | 22.5¢ | 21.5¢ | $199.8K | 920.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 85201 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 7845 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85201 | 0.215 |
6 | 155371 | 0.210 |
3 | 79540 | 0.205 |
16 | 274820 | 0.200 |
2 | 8000 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 7845 | 1 |
0.230 | 6750 | 2 |
0.235 | 30000 | 1 |
0.240 | 78995 | 1 |
0.245 | 21000 | 2 |
Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |